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Background: Toll-like receptor 3 (TLR3) recognizes dou-
ble-stranded RNA (dsRNA) and induces inflammation. In this 
study we attempted to ascertain if there are endogenous 
host molecules controlling the production of cytokines and 
chemokines. Two candidates, ribosomal protein L19 and L22, 
were analyzed to determine if they influence cytokine pro-
duction followed by TLR3 activation. In this study we report 
that L19 acts upon production of IP-10 or IL-8 differently in 
glioblastoma cells. Methods: L19 or L22 was transfected into 
HEK293-TLR3, A549 or A172 cells. After treatment with sev-
eral inhibitors of NF-kB, PI3K, p38 or ERK, production of IL-8 
or IP-10 was measured by ELISA. siRNA was introduced to 
suppress expression of L19. After Vesicular stomatitis virus 
infection, viral multiplication was measured by western blot. 
Results: L19 increased ERK activation to produce IL-8. In 
A172 cells, in which TLR3 is expressed at endosomes, L19 
inhibited interferon regulatory factor 3 (IRF3) activation and 
IP-10 production to facilitate viral multiplication, whereas 
L19 inhibited viral multiplication in A549 cells bearing TLR3 
on their cell membrane. Conclusion: Our results suggest that 
L19 regulates TLR3 signaling, which is cell type specific and 
may be involved in pathogenesis of autoimmune diseases 
and chronic inflammatory diseases.
[Immune Network 2011;11(3):155-162]
INTRODUCTION
Toll-like receptor 3 (TLR3), the typical anti-viral pattern recog-
nition receptor (PRR), recognizes dsRNA and activates nuclear 
factor-kB (NF-kB), interferon regulatory factor 3 (IRF3), and 
AP-1. TLR3 generally mediates anti-viral immunity, however, 
in some infections, cytokines or chemokines produced by 
TLR3 change the host immunological niche to facilitate viral 
replication. Therefore, there is some debate about the role 
of TLR3 in viral infection. For example, TLR3 binds to dsRNA 
of the West Nile virus (WNV), which is produced during viral 
replication. When TLR3 deficient mice are infected with 
WNV, the virus multiply and encephalomyelitis does not se-
verely progress. Pathological findings were less than control 
mice, in which the blood-brain barrier is broken after viral 
infection and TNF-α or IL-β is produced via TLR3 activation 
(1). The lung is another organ where TLR3 is abundantly 
expressed. Invasion of the influenza A virus increases TLR3 
expression and leads to acute pneumonitis (2). In TLR3 
knock-out mice, the survival time is longer than in wild type 
mice, although considerable amount of virus is detected in 
the lung. These two reports showed that lack of TLR3 inhibits 
an unfavorable immune response to the host by modulating 
activation of the innate immune response or CD8＋T cells. 
Therefore, although the TLR3 immune response inhibits viral 
multiplication, it may also induce harmful and pathological 
inflammation (3,4). TLR3 signaling controls pathological phe-
nomena by decreasing mucus secretion in respiratory syncy-
tial virus (RSV) infection rather than acting directly on inhibit-
ing viral multiplication. When TLR3 deficient mice are in-
fected with RSV, T helper 2 (TH2) cytokines are induced and 
mucus secretion increases, which is the representative finding 
in RSV infection.Therefore, these diverse TLR3 immune re-
actions depend on virus type, the amount of virus, infection 
route, target cells and infection time (5,6).
  In respect to pathogens, several viral components are 
known to regulate innate immunity. NS1 of the influenza A 
virus (7), E3 of the vaccinia virus (8), and VP39 of the ebola 
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virus (9) bind to viral dsRNA and interfere the binding with 
TLR3. NS3-4A (10) of the hepatitis C virus inhibits TLR3 sig-
naling by degrading Toll-interleukin 1 receptor domain-con-
taining adapter inducing interferon-β (TRIF).
  The ribosome consists of a small 40S subunit and a large 
60S subunit. These subunits are composed of 4 RNA species 
and approximately 80 structurally distinct proteins. RPL19 is 
found in the large ribosomal subunit (60S) of eukaryotes and 
archaea. RPL19 consists of two small globular domains con-
nected by an extended segment. RPL19 is located towards the 
surface of the large subunit, with one exposed end involved 
in forming the inter-subunit bridge with the small subunit. 
The other exposed end is involved in forming the translocon 
binding site, along with L22, L23, L24, L29, and L31e subunits 
(11,12).
  EBER (Epstein-Barr virus encoded small RNA)-1 produced 
in cells infected with EBV (Epstein-Barr virus) is a 167 bp 
non-translated RNA and has a stable stem-loop. EBER inter-
acts with PKR (RNA dependent protein kinase) to inactivate 
PKR and further inhibits IFN-induced apoptosis of host cells. 
EBER binds to L22 through stem-loop III and IV. L22 and PKR 
compete with each other to bind to the same region of 
EBER-1. When EBV infection occurs, L22 binds to EBER 
which blocks PKR activation and maintains the host anti-viral 
immune response (13,14).
  In this study we attempted to determine if there are endog-
enous host molecules controlling the production of cytokines 
and chemokines. Two candidates, ribosomal protein L19 and 
L22, were analyzed to determine if they influence cytokine 
production followed by TLR3 activation.
MATERIALS AND METHODS
Reagents
The p38 MAPK inhibitor SB203580, JNK inhibitors (I, II), PI3K 
inhibitors (LY294002, Wortmannin), NF-κB inhibitor BAY11- 
7082 and the MEK1/2 inhibitor UO126 were obtained from 
Calbiochem (San Diego, CA., USA) and each dissolved in di-
methyl sulfoxide to achieve a stock concentration of 20 mM. 
For western blot analysis, anti-IκB-α or anti-phospho- IκB-
α, anti-IRF3 or anti-phospho-IRF3, anti-ERK or anti-phos-
pho-ERK, anti-phospho-JNK, anti-phospho-p38, anti- phos-
pho-AKT, anti-phospho-PTEN, anti-phospho-PDK1, and an-
ti-RIG-I antibodies were all purchased from Cell Signaling 
Technology (Beverly, MA, USA). Anti-V5 and anti-VSV G anti-
body were purchased from Invitrogen. For secondary anti-
bodies, goat anti-mouse IgG and goat anti-rabbit IgG (Jackson 
Immuno Research, Baltimore, MD, USA) were used.
Cell culture
HEK293-TLR3 cell lines were purchased from InvivoGen and 
were then maintained and subcultured in 10% fetal bovine 
serum (FBS; Gibco BRL, Grand Island, NY, USA) -Dulbecco’s 
modified Eagle’s medium (DMEM; Gibco BRL, Grand Island, 
NY, USA) at 37oC in 5% CO2. The cell culture medium con-
tained 10μg/ml of blasticidin (InvivoGen, San Diego, CA, 
USA) as selection antibiotics. The human glioblastoma cell 
line A172 was obtained from ATCC (CRL-1620) and main-
tained in minimal essential medium (MEM, Gibco BRL, Grand 
Island, NY, USA) supplemented with 10% FBS and penicillin 
and streptomycin (Gibco BRL, Grand Island, NY, USA) at 
37oC in 5% CO2. A549 cells originated from lung epithelial 
carcinoma (CCL-185TM, ATCC, Manassas, VA, USA) and were 
cultured in MEM containing 10% FBS, penicillin and 
streptomycin.
Transient transfection and luciferase reporter gene 
assay
Luciferase reporter gene assay was performed with p133-Luc 
(IL-8 promoter, kindly provided by Professor Naofumi 
Mukaida, Kanazawa University, Japan) and pISRE-Luc plas-
mid (Stratagene, West Cedar Creek, TX, USA). HEK293- TLR3 
or A172 cells were grown in 24-well plates with 10% 
FBS-DMEM at 37oC in 5% CO2. Cells were cotransfected with 
0.05 mg/ml p133-Luc, pISRE-Luc plasmids, and pCMV-β- 
galactosidase vectors (Promega, Madison, WI, USA) using 
FuGENE 6 Reagent (Roche, Indianapolis, IN, USA). After 24 
hrs, cells were stimulated with poly(I:C) (10μg/ml) 
(InvivoGen, San Diego, CA, USA) for 6 hrs, and cell extracts 
were prepared. Luciferase activity was measured using a 
Luciferase Reporter Assay System (Promega, Madison, WI, 
USA) and β-galactosidase activity was measured using O-ni-
trophenyl-β-D-galactopyranoside (Sigma-Aldrich, St. Louis, 
MI, USA) as the substrate. Luciferase activity was normalized 
for transfection efficiency with β-galactosidase activity.
ELISA
A172 cells transiently transfected with L19 or a control vector 
(pcDNA3.1/V5) were treated with poly(I:C) (25μg/ml). After 
the indicated treatment with poly(I:C), culture medium was 
collected to measure IP-10 or IL-8 production. IP-10 or IL-8 
in the culture supernatant was quantified using commercial 
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Figure 1. Effect of L19 on poly(I:C)-induced activation of ISRE promoter and IP-10 production. (A) HEK293-TLR3 cells were transfected with
empty vectors or expression vectors for L19 together with ISRE (IRF3 promoter) reporter plasmids. 18 hrs after transfection, cells were treated 
with poly(I:C) (10μg/ml) for 6 hrs in the presence of 25μM chloroquine (inhibitor of endosome acidification) or no inhibitor. After poly(I:C)
treatment luciferase assays were performed. Luciferase activity is normalized to β-galactosidase activity; results are means±s.d. from three separate
transfections. (B) A172 cells were transfected with empty vectors or V5-tagged L19 plasmid. 18 hrs after transfection, cells were stimulated with 
poly(I:C) (25μg/ml) in the presence or absence 25μM chloroquine for 8 or 24 hrs and thensupernatants were measured by ELISA for IP-10
production. Values represent the mean±S.E. of triplicate samples.
specific ELISA kits (BD Biosciences, Franklin Lakes, New 
Jersey, USA) according to the manufacturer’s instructions. 
The experiments were performed in triplicate. 
Western blot analysis
For transient transfection, HEK293 or A172 cells (∼1×106) 
were transfected with L19 plasmids for 24 hrs. The transfected 
cells were lysed in 300μl of lysis buffer [20 mMTris, pH 7.5, 
150 mM NaCl, 1% Triton, 1mM ethylenediaminetetraacetic 
acid (EDTA), 10μg/ml aprotinin, 10μg/ml leupeptin, 1 mM 
phenylmethylsulfonyl fluoride].
  Total protein from either HEK293 or A172 cells transfected 
with L19 or control plasmids were separated with 10∼12% 
SDS-PAGE and transferred to nitrocellulose membranes. The 
blots were blocked in PBS-0.1%Tween 20 (PBST) containing 
5% non-fat milk and incubated with appropriate primary anti-
bodies at a dilution of 1：1,000. After three washes in PBST, 
peroxidase-conjugated secondary antibodies were incubated 
at a dilution of 1：5,000, washed three times with PBST and 
developed with an ECL system (GE Healthcare, Buckingham-
shire, UK).
RNAi assay
StealthTMsiRNAs were obtained from Invitrogen. Invitrogen 
supplied the sequences of the L19 siRNA and StealthTMRNAi 
negative control duplexes. StealthTMsiRNA is chemically modi-
fied dsRNA that was developed to overcome the limitation 
of traditional siRNA. StealthTMRNAi negative control duplex 
does not induce the interferon-mediated stress response 
pathway. The targeted sequence of L19 StealthTMsiRNA was 
5’-CUU GGA UAA AGU CUU GAU GAU CUCC-3’. 
HEK293/L19 cells transfected with the indicated siRNAs were 
then stimulated with poly(I:C) (20μg/ml) and activation of 
IRF3, and NF-κB, and protein levels of L19 were measured 
by western blot.
Vesicular stomatitis virus infection
Vesicular stomatitis virus (VSV, Indiana serotype, Mudd-Sum-
mmers strain) was propagated in Vero cells. African green 
monkey kidney epithelial Vero cells were maintained in 
DMEM supplemented with 10% FBS. The viral titer was moni-
tored by a plaque assay using Vero cells. A549 cells were 
transfected with either V5-tagged L19 genes, L22, or mock 
vectors. Cells were grown to 80∼90% confluence for 24 hrs 
and then infected with 1 MOI of VSV for 6 hrs in serum free 
medium.
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Figure 2. Effect of L19 on poly(I:C)-induced activation of IL-8 promoter and IL-8 production. (A) A172 cells were transfected with empty vectors 
or expression vectors for L19 together with p133-Luc (IL-8 promoter) reporter plasmids. 18 hrs after transfection, cells were treated with poly(I:C)
(25μg/ml) for 6 hrs. After poly(I:C) treatment luciferase assays were performed. Luciferase activity is normalized to β-galactosidase activity; results
are means±s.d. from three separate transfections. (B) A172 cells were transfected with empty vectors or V5-tagged L19 plasmid. 18 hrs after 
transfection, cells were stimulated with poly(I:C) (25μg/ml) in the presence or absence 25μM chloroquine (inhibitor of endosome acidification)
for 6 or 24 hrs and then supernatants were measured by ELISA for IL-8. Values represent the mean±S.E. of triplicate samples.
RESULTS
Effect of L19 on induction of IP-10 and IL-8 followed by 
poly(I:C) administration
To assess the effect of L19 on the production of IRF3 depend-
ent chemokines and IP-10, ISRE promoter activity, and NF-κB 
or ERK dependent IL-8 production was evaluated. First, 
HEK293 cells bearing TLR3 (HEK293/TLR3) were transfected 
with L19. Then 25μg/ml of poly(I:C) was administrated for 
6 hrs with or without chloroquine. As a result, ISRE activity 
decreased according to the transfected amount of L19 (Fig. 
1A). A172 cells, glioblastoma cells expressing TLR3, were 
transfected with L19 and treated with poly(I:C). After the in-
dicated time, culture supernatants were harvested and the 
amount of IP-10 and IL-8 produced was measured by ELISA. 
Production of IP-10 or IL-8 changed in a L19 dose-dependent 
manner at only later time points (24 and 16 hrs after poly(I:C) 
treatment, respectively) but not at early time points (8 and 
6 hrs after poly(I:C) treatment, respectively) (Figs. 1B and 
2A). IL-8 promoter activity increased dependently with the 
L19 dose (Fig. 2B). These results suggest that TLR3 signaling 
is influenced by L19.
Effect of L19 on phosphorylation of NF-κB or IRF-3
Using cells over-expressing or lacking L19, immunoblotting of 
IκBα and IRF3 was performed. In HEK293 cells over-ex-
pressing L19, IκBα was phosphorylated 30 min after 
poly(I:C) stimulation, which started early when compared to 
the control vector (Fig. 3A). When the expression of L19 was 
inhibited by siRNA, IRF3 activation increased, however activa-
tion of IκBα decreased slightly (Fig. 3B). These results sug-
gest that inhibition of IP-10 produciton by L19, elicits strong 
activation of the TLR3-TRIF-NF-kB pathway to compensate 
decreased IRF3 activation and further decreased production 
of IP-10. A similar phenomenon was reported in a prior study 
demonstrating that the TRIF-dependent pathway is activated 
when the MyD88 dependent pathway is inhibited.
Identification of signaling molecules or transcription 
factors participating in production of IP-10 or IL-8
Several inhibitors including JNKI, JNKII, SB203580, U0126, 
BAY11-7082, LY294002, and wortmannin were used to further 
detail the important pathways to produce IP-10 and IL-8. 
Inhibitors were pretreated and poly(I:C) was administrated. 
ELISA revealed that IP-10 was decreased by either the p38 
inhibitor (SB203580), PI3K inhibitor (LY294002, wortmannin), 
or NF-κB inhibitor (BAY11-7082) (Fig. 4A). IL-8 production 
was inhibited most effectively by treatment with ERK inhibitor 
(U0126).Additionally, NF-kB inhibitor (BAY11-7082) and PI3K 
inhibitor (LY294002) blocked the signaling to produce IL-8 
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Figure 4. PI3 kinase plays differential roles in the production of 
TLR3-mediated IP-10 and IL-8. A172 cells were incubated with 
medium alone or with poly(I:C) (10μg/ml) for 18 hrs in the absence
or presence of various pharmacological inhibitors at the indicated 
concentrations: JNK I or II, SB203580, U0126, BAY11-7082, LY294002
and Wortmannin. Each inhibitor was added 45 min before poly(I:C)
stimulation. After treatment with poly(I:C), supernatants were measur-
ed by ELISA for IP-10 production (A) and IL-8 production (B). Values
represent the mean±S.E. of triplicate samples.
Figure 3. Effect of L19 on activation of IRF3 or IκBα in TLR3 signal-
ing. (A) HEK293 cells grown in 60mm plates were transfected with
control (pcDNA3.1) or V5-tagged L19. 48 hrs after transfection, cells
were stimulated with 20μg/ml poly(I:C) for the indicated time. 
Phosphorylated IκBα (p-IκBα) and total IκBαwere determined by
western blotting using anti-p-IκBα (Ser32) and anti-IκBα anti-
bodies. The expression level of L19 in the cell lysates was analyzed 
with anti-V5 antibody. To confirm equal loading, membranes were 
re-probed with anti-α-tubulin antibody. (B) siRNA oligo targeting L19 
or negative control were transfected into L19 expressing HEK293 
(HEK293-L19) cells to silence the expression of L19. 48 hrs after 
transfection, cells were stimulated without or with 20μg/ml of poly
(I:C) for the indicated time. Total cell lysates analyzed by immuno-
blotting with anti-phospho-IRF3 (Ser396) or anti-IRF-3 antibody, 
anti-p-IκBα (Ser32) or anti-IκBα antibodies. The efficiency of L19 
RNAi was confirmed by immunoblotting with anti-V5 (L19) antibody.
(Fig. 4A). On the contrary, PI3K inhibitor (wortmannin) in-
duced IL-8 production (Fig. 4B).
Effect of L19 on ERK phosphorylation
As shown above, L19 has an inhibitory effect on IP-10 pro-
duction but an stimulatory effect on IL-8 production in A172 
cells. We then attempted to identify the molecules respon-
sible for IL-8 induction in cooperation with L19. A172 cells 
were transfected with L19 and then pretreated with LY294002 
and wortmannin. Activation of ERK, IKBα, JNK, p38, PDK1, 
Akt, and PTEN were then assessed after poly(I:C) stimula-
tion. Results showed that LY294002 inhibited activation of all 
the tested signaling molecules, whereas the decreased phos-
phorylation of ERK, NF-κB, PDK1, and PTEN by wortmannin 
was recovered by transfection with L19 in a dose-dependent 
manner (Fig. 5A).We also assessed the phosphorylation of 
ERK, JNK, Akt, and PDK from 1-12 hrs after poly(I:C) 
stimulation. Phosphorylation of ERK increased with trans-
fection of L19 in a dose-dependent manner at 2 hrs (Fig. 5B) 
and at 12 hrs (Fig. 5C) after poly(I:C) treatment. However, 
activation of JNK and PDK decreased with transfection of L19 
in a dose-dependent manner at 2 hrs after poly(I:C) treatment 
and phosphorylation of Akt increased at 1 hr after poly(I:C) 
treatment (Fig. 5B). These results suggest that L19 increases 
the activation of ERK, however decreases the activation of 
JNK and PDK.
Effect of L19 on anti-viral response in association 
with L22
Next we demonstrated the effect of L19 on VSV infection us-
ing A549 cells originating from lung epithelial cells, where the 
major expression site of TLR3 is at the cell membrane. RIG 
expression was also inhibited by introducing shRNA into 
these cells. VSV multiplication was then evaluated by measur-
ing levels of viral G protein 24 hrs after initial viral infection. 
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Figure 5. Effects of PI3K inhibitors together with L19 on TLR-mediated activation of intracellular signaling molecules. (A) A172 cells were transfected
with empty vectors or V5-tagged L19 plasmid. 18 hrs after transfection, cells were stimulated with poly(I:C) (25μg/ml) in the presence or absence
LY294002 (LY, 20μM) and wortmannin (Wort, 5μM) for 20 hrs and then total cell lysates analyzed by immunoblotting with anti-phospho-ERK,
-IκBα, -JNK, -p38, -PDK1, -Akt, -PTEN antibodies. To confirm equal loading, membranes were re-probed with anti-α-tubulin antibody. (B) A172
cells were transfected with empty vectors or V5-tagged L19 plasmid. 20 hrs after transfection, cells were stimulated with poly(I:C) (25μg/ml)
for 60 or 120 min (B) and 12 hrs (C) and then total cell lysates analyzed by immunoblotting with anti-phospho-ERK, -JNK, -PDK1, -Akt antibodies.
The expression level of exogenous or endogenous L19 in the cell lysates were analyzed with anti-L19 monoclonal antibody. To confirm equal
loading, membranes were re-probed with anti-α-tubulin antibody.
Figure 6. Effect of L19 together with L22 in anti-viral immunity. A549
cells treated with RIG-I siRNAs were transfected with L19 or L22. 24
hrs after transfection, cells were infected with 1MOI VSV for 6 hrs 
and then extracts from VSV-infected cells were analyzed by western
blotting with antibodies against G protein (VSV), RIG-I, phospho-IRF3
(Ser396) and phospho-PKR (Thr451).
When RIG-1 and L22 were transfected together, viral multi-
plication was inhibited and RIG-1 activation was induced 
(Fig. 6).
  When L19 were transfected in A549 cells, viral multi-
plication was inhibited (Fig. 6). Especially L19 induced RIG-1 
expression and activation of IRF3 (Fig. 6). This finding is con-
trary to the results acquired with A172 cells and suggests that 
the effect of L19 varies with different cell types and the local-
ization site of TLR3.
DISCUSSION
Recently the influence of TLR members has been reported in 
various inflammatory and immune disorders such as sepsis, 
asthma, atherosclerosis, Alzheimer’s disease, and rheumatoid 
arthritis (15,16). With certain genetic predispositions, TLR sig-
naling leads to overt symptoms in various autoimmune dis-
eases, for example, systemic lupus erythematosus, multiple 
sclerosis, and inflammatory bowel disease (17). Therefore, 
TLR molecules and related signaling have become potential 
therapeutic targets and are under evaluation.
  Here we report that L19 modulates TLR3 signaling induced 
by poly(I:C). In A172 cells, a glioblastoma cell line, over-ex-
pression of L19 inhibits production of IP-10 and increases 
production of IL-8. Generally TLR3 activation following viral 
infection increases production of TNF-α, IL-1β, IL-6, IP-10, 
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and IL-8 to eliminate pathogens (18). However, this response 
is cell type specific. For example, TLR3 activation increased 
the production of TNF-α, RANTES, and MIP-1α in murine 
fetalskin-derived cultured mast cells (FSMC), whereas it in-
duced production of IL-6 and IL-12, not chemokines, in mi-
croglial cells (19). In another experiment, respiratory syncytial 
virus (RSV) was infected into two different cells, MRC-5 
(human lung fibroblasts) and A549 (lung epithelial cells) cells, 
respectively. In this particular study, chemokines such as 
IP-10, CCL5 and IL-8 were induced and the expression of 
TLR3 increased in A549 cells. However, TLR3 knock-down 
using RNAi decreased production of IP-10 and CCL5, whereas 
IL-8 was either not affected or rather increased in MRC5 cells 
(20). All these reports suggest that signaling induced by TLR3 
differs with cell types.
  TLR3 signaling induces activation of IKK, ERK, and JNK 
and further produces TNF-α, IL-1β, IL-6, and IL-8. The 
pharmacological inhibitor of JNK, SP600125, blocked pro-
duction of IP-10 and IL-8. The ERK inhibitor study suggests 
ERK is responsible for inhibiting IL-8, but not IP-10 (21,22). 
PI3K is necessary for full activation of IRF3, an important tran-
scription factor involved in the production of IFN-β and 
IP-10, whereas it inhibits activation of GSK-3β and ERK. 
During TLR3 signaling PI3K contributes to IP-10 production 
by activating IRF3, however it inactivates GSK-3β and ERK 
to decrease IL-8 production (23). All of these studies demon-
strate that the end products of TLR3 signaling are affected by 
major signaling pathways and that each responds in a differ-
ent manner.
  First, to identify which signaling molecules were respon-
sible for IP-10 and IL-8 production in association with L19, 
inhibitors were used against JNKI, JNKII, EKR, p38, PI3K, and 
NF-kB in A172 cells. As a result, we found that through acti-
vation of both NF-κB and ERK, L19 further enhanced the 
increase in production of IL-8 by poly(I:C). When L19 was 
over-expressed, the phosphorylation of IκB-α and ERK in-
creased with L19 in a dose dependent manner. Moreover, 
knock-down of L19 lead to decreased phosphorylation of 
IκB-α at an early stage after poly(I:C) treatment. The find-
ing that IRF3-dependent IP-10 production was inhibited by ei-
ther LY294002 or wortmannin suggests that the PI3K pathway 
is affected by L19 involvement. Furthermore, phosphorylation 
of IRF3 increased with knock-down of L19. These results sug-
gest that introduction of L19 into cells inhibits the TLR3- 
TRIF-PI3K-IRF3 pathway and the production of IP-10. At the 
same time, L19 induces activation of the TLR3-TRIF-NF-κB 
and ERK pathway and production of IL-8. Although LY294002 
and wortmannin belong to the same family of PI3K inhibitors, 
the underlying mechanism of action is different. Wortmannin 
inhibits myosin light chain kinases and PI3K-related protein 
kinases, whereas LY294002 is the effective inhibitor for casein 
kinase2 (24). This explains our discordant result showing that 
TLR3-mediated cytokine production increases with wortman-
nin treatment, but decreases with LY294002.
  Next, A549 cells, lung epithelial cells, were infected with 
VSV. Introduction of L19 inhibited VSV replication. Another 
ribosomal protein, L22, also blocked VSV multiplication. 
These results are contrary to those found with A172 cells, in 
which L19 induced inactivation of the TLR3-TRIF-PI3K-IRF3 
pathway and decreased the production of IP-10. These find-
ings demonstrate that the effect of L19 on TLR3 signaling is 
cell type-specific and dependent upon the localization of 
TLR3 in cells.
  Therefore, with these results we suggest that L19 could 
have a pivotal role in viral multiplication dependent upon cell 
type and may be involved in the pathogenesis of autoimmune 
diseases and chronic inflammatory diseases.
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